Skip to content

A study to evaluate the safety of excessive ingestion of licorice flavonoid oil for healthy adults.

A study to evaluate the safety of excessive ingestion of licorice flavonoid oil for healthy adults. - A study to evaluate the safety of excessive ingestion of licorice flavonoid oil for healthy adults.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000030307
Enrollment
20
Registered
2017-12-18
Start date
2017-12-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Ingestion of licorice flavonoid oil containing food (5 soft gels per day, 4 weeks)

Sponsors

TTC Co.,Ltd
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy males and females aged 20-69 years.

Exclusion criteria

Exclusion criteria: (1)With allergy to the study foods. (2)Subjects who has a disease under treatment. (3)Subjects who has under treatment or a history of serious disease (e.g., diabetes, liver disease, kidney disease, heart disease or cancer). (4)Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire. (5)Subjects who constantly take in supplement richly containing licorice glabra polyphenol or licorice flavonoid oil. (6)Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination at the screening. (7)Subjects who have habits affecting research results, such as doing shift work day and night, or Subjects who have a plan that affect research results such as day and night shift work or going overseas. (8)Subjects who have participated in other clinical study within the last one month prior to the current study. (9)Subjects who are planned to become pregnant after informed consent for the current study or are pregnant or lactating. (10)Subjects who are judged as unsuitable by doctor for other reasons.

Design outcomes

Primary

MeasureTime frame
Hematology test Blood biochemistry test Urinalysis Blood pressure/pulsation Body weight Doctor's questions Adverse event

Countries

Japan

Contacts

Public ContactSaki Fukuchi

TTC CO., LTD. Clinical Research Planning Department

s.fukuchi@ttc-tokyo.co.jp03-5459-5329

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026